Clinical Trial Update: Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network

View source ↗

Summary

A clinical trial update reports on the efficacy and tolerability of Bevacizumab for severe liver involvement with high cardiac output in hereditary hemorrhagic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia
• Pulmonary Hypertension

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension | Status: ENROLLING_BY_INVITATION